肝活检病理与心脏移植患者预后的关系

Lauren S. Eichenwald MD , Raffi Karagozian MD , Adam J. Eichenwald PhD , John Morrissey MD MBA , Saurav Kini MD , Ariella Stein MSCIS-HI , Amanda R. Vest MBBS MPH
{"title":"肝活检病理与心脏移植患者预后的关系","authors":"Lauren S. Eichenwald MD ,&nbsp;Raffi Karagozian MD ,&nbsp;Adam J. Eichenwald PhD ,&nbsp;John Morrissey MD MBA ,&nbsp;Saurav Kini MD ,&nbsp;Ariella Stein MSCIS-HI ,&nbsp;Amanda R. Vest MBBS MPH","doi":"10.1016/j.jhlto.2024.100187","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with advanced heart failure needing heart transplant commonly suffer liver dysfunction. However, there is limited data on the impact of liver fibrosis on outcomes for heart transplant (HT) candidates. We determine the relationship between liver fibrosis severity and mortality rates for HT patients.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of adults listed for HT who underwent a liver biopsy for evaluation of early or advanced liver fibrosis from August 12, 2004 to February 16, 2022. Trend analysis was performed using Cox proportional hazard model, controlling for MELD-XI. At-risk period starts at the time of waitlist; the end of the follow-up period was mortality on the waitlist, mortality post-HT, or administrative censoring at the end of the study.</div></div><div><h3>Results</h3><div>There was no significant difference in the survival of patients with advanced fibrosis and early fibrosis over time (HR 1.54, CI 0.59–4.02, <em>p</em> = 0.5). Similarly, there was also no significant survival difference within groups who did (HR 0.78, CI = 0.26–2.33, <em>p</em> = 0.8) or did not (HR 1.00, CI 0.09–11.43, <em>p</em> = 0.9) receive transplants. However, most transplants were performed in patients with no or early fibrosis.</div></div><div><h3>Conclusion</h3><div>There was no significant difference in the survival rates between HT candidates with and without advanced fibrosis on the waitlist and post-HT, challenging the notion that advanced fibrosis should be an absolute contraindication for HT. However, our findings are limited by the small sample size, retrospective design, and focus on patients already deemed suitable for transplantation. These limitations highlight the need for prospective studies involving broader patient populations, including those excluded from transplant candidacy due to severe fibrosis or cirrhosis. Future research should evaluate whether pre-transplant liver biopsy is necessary for all HT candidates or if clinical assessments can adequately stratify risk.</div></div><div><h3>Lay summary</h3><div>This study found that the presence of advanced liver injury did not confer a difference in the waitlist and post heart transplant (HT) survival rates of patients on the HT transplant list. This finding suggests that patients listed for transplant may not need to undergo a liver biopsy as part of the transplant work up.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100187"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of liver biopsy pathology on outcome of patients undergoing heart transplantation\",\"authors\":\"Lauren S. Eichenwald MD ,&nbsp;Raffi Karagozian MD ,&nbsp;Adam J. Eichenwald PhD ,&nbsp;John Morrissey MD MBA ,&nbsp;Saurav Kini MD ,&nbsp;Ariella Stein MSCIS-HI ,&nbsp;Amanda R. Vest MBBS MPH\",\"doi\":\"10.1016/j.jhlto.2024.100187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Patients with advanced heart failure needing heart transplant commonly suffer liver dysfunction. However, there is limited data on the impact of liver fibrosis on outcomes for heart transplant (HT) candidates. We determine the relationship between liver fibrosis severity and mortality rates for HT patients.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of adults listed for HT who underwent a liver biopsy for evaluation of early or advanced liver fibrosis from August 12, 2004 to February 16, 2022. Trend analysis was performed using Cox proportional hazard model, controlling for MELD-XI. At-risk period starts at the time of waitlist; the end of the follow-up period was mortality on the waitlist, mortality post-HT, or administrative censoring at the end of the study.</div></div><div><h3>Results</h3><div>There was no significant difference in the survival of patients with advanced fibrosis and early fibrosis over time (HR 1.54, CI 0.59–4.02, <em>p</em> = 0.5). Similarly, there was also no significant survival difference within groups who did (HR 0.78, CI = 0.26–2.33, <em>p</em> = 0.8) or did not (HR 1.00, CI 0.09–11.43, <em>p</em> = 0.9) receive transplants. However, most transplants were performed in patients with no or early fibrosis.</div></div><div><h3>Conclusion</h3><div>There was no significant difference in the survival rates between HT candidates with and without advanced fibrosis on the waitlist and post-HT, challenging the notion that advanced fibrosis should be an absolute contraindication for HT. However, our findings are limited by the small sample size, retrospective design, and focus on patients already deemed suitable for transplantation. These limitations highlight the need for prospective studies involving broader patient populations, including those excluded from transplant candidacy due to severe fibrosis or cirrhosis. Future research should evaluate whether pre-transplant liver biopsy is necessary for all HT candidates or if clinical assessments can adequately stratify risk.</div></div><div><h3>Lay summary</h3><div>This study found that the presence of advanced liver injury did not confer a difference in the waitlist and post heart transplant (HT) survival rates of patients on the HT transplant list. This finding suggests that patients listed for transplant may not need to undergo a liver biopsy as part of the transplant work up.</div></div>\",\"PeriodicalId\":100741,\"journal\":{\"name\":\"JHLT Open\",\"volume\":\"7 \",\"pages\":\"Article 100187\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JHLT Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950133424001368\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHLT Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950133424001368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:晚期心力衰竭需要心脏移植的患者通常伴有肝功能障碍。然而,关于肝纤维化对心脏移植(HT)候选人预后影响的数据有限。我们确定肝纤维化严重程度与HT患者死亡率之间的关系。方法对2004年8月12日至2022年2月16日期间接受肝活检以评估早期或晚期肝纤维化的成人进行回顾性队列研究。采用Cox比例风险模型进行趋势分析,控制MELD-XI。高危期从排队时间开始;随访期结束时是等待名单上的死亡率,ht后的死亡率,或研究结束时的行政审查。结果晚期纤维化和早期纤维化患者的生存率随时间变化无显著差异(HR 1.54, CI 0.59-4.02, p = 0.5)。同样,接受移植组(HR 0.78, CI = 0.26-2.33, p = 0.8)和未接受移植组(HR 1.00, CI 0.09-11.43, p = 0.9)的生存率也无显著差异。然而,大多数移植是在没有纤维化或早期纤维化的患者中进行的。结论:在等待名单上有和没有晚期纤维化的HT候选人和HT后的生存率没有显著差异,挑战了晚期纤维化应该是HT绝对禁忌症的观念。然而,我们的研究结果受到样本量小、回顾性设计以及关注已经被认为适合移植的患者的限制。这些局限性突出了前瞻性研究的需要,涉及更广泛的患者群体,包括那些因严重纤维化或肝硬化而被排除移植候选的患者。未来的研究应该评估移植前肝活检是否对所有HT候选者都有必要,或者临床评估是否可以充分地对风险进行分层。摘要:本研究发现,晚期肝损伤的存在并没有给心脏移植患者的等待名单和移植后(HT)生存率带来差异。这一发现表明,列入移植名单的患者可能不需要进行肝活检作为移植工作的一部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association of liver biopsy pathology on outcome of patients undergoing heart transplantation

Background

Patients with advanced heart failure needing heart transplant commonly suffer liver dysfunction. However, there is limited data on the impact of liver fibrosis on outcomes for heart transplant (HT) candidates. We determine the relationship between liver fibrosis severity and mortality rates for HT patients.

Methods

A retrospective cohort study of adults listed for HT who underwent a liver biopsy for evaluation of early or advanced liver fibrosis from August 12, 2004 to February 16, 2022. Trend analysis was performed using Cox proportional hazard model, controlling for MELD-XI. At-risk period starts at the time of waitlist; the end of the follow-up period was mortality on the waitlist, mortality post-HT, or administrative censoring at the end of the study.

Results

There was no significant difference in the survival of patients with advanced fibrosis and early fibrosis over time (HR 1.54, CI 0.59–4.02, p = 0.5). Similarly, there was also no significant survival difference within groups who did (HR 0.78, CI = 0.26–2.33, p = 0.8) or did not (HR 1.00, CI 0.09–11.43, p = 0.9) receive transplants. However, most transplants were performed in patients with no or early fibrosis.

Conclusion

There was no significant difference in the survival rates between HT candidates with and without advanced fibrosis on the waitlist and post-HT, challenging the notion that advanced fibrosis should be an absolute contraindication for HT. However, our findings are limited by the small sample size, retrospective design, and focus on patients already deemed suitable for transplantation. These limitations highlight the need for prospective studies involving broader patient populations, including those excluded from transplant candidacy due to severe fibrosis or cirrhosis. Future research should evaluate whether pre-transplant liver biopsy is necessary for all HT candidates or if clinical assessments can adequately stratify risk.

Lay summary

This study found that the presence of advanced liver injury did not confer a difference in the waitlist and post heart transplant (HT) survival rates of patients on the HT transplant list. This finding suggests that patients listed for transplant may not need to undergo a liver biopsy as part of the transplant work up.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信